• Pierre-Yves Hatron, Isabelle Tillie-Leblond, David Launay, Eric Hachulla, Anne Laure Fauchais, and Benoît Wallaert.
• Service de médecine interne, Centre national de référence des maladies systémiques et auto-immunes rares (sclérodermie), université Lille2, CHRU de Lille, place de Verdun, 59037 Lille, France. pyhatron@chru-lille.fr
• Presse Med. 2011 Jan 1;40(1 Pt 2):e49-64.

AbstractSjögren's syndrome is a chronic inflammatory disorder characterized by lymphocytic infiltration of exocrine glands, mainly the lacrimal and salivary glands. However, extraglandular organ systems may frequently be involved, including the lungs. Although subclinical pulmonary inflammation exists in more than 50% of patients, clinically significant pulmonary involvement affects approximately 10% of patients and may be the first manifestation of the disease. The entire respiratory tract may be involved, with a wide spectrum of manifestations including xerotrachea and bronchial sicca, obstructive small airway disease, various patterns of interstitial lung disease, lymphoinfiltrative or lymphoproliferative lung disease, such as lymphoma (usually of MALT type), pulmonary hypertension, pleural involvement, lung cysts, and pulmonary amyloidosis.Copyright © 2010 Elsevier Masson SAS. All rights reserved.

12 keywords...

hide…